

Prostate Cancer GComm1 - Committee Meeting

Date: 08/09/21

Location: Virtual

Minutes: Final

Committee members present:	
Ann Hoskins (AH)	Present for notes 1 – 9
Tristan Barrett (TB)	Present for notes 1 – 9
Guy Chetiyawardana (GC)	Present for notes 1 – 9
Steve Hazell (SH)	Present for notes 1 – 9
Sheba Joseph (SJ)	Present for notes 1 – 9
John Marshall (JM)	Present for notes 1 – 9
Samuel Merriel (SM)	Present for notes 1 – 9
Krishna Narahari (KN)	Present for notes 1 – 9
Brian Shine (BS)	Present for notes 1 – 9
Santhanam Sundar (SS)	Present for notes 1 – 9
Joanne Wortley (JW)	Present for notes 1 – 9

In attendance:		
Steph Armstrong (SA)	Technical Analyst - Health Economics	Present for notes 1 – 9
Lucy Beggs (LB)	Technical Adviser – Health Economics	Present for notes 1 – 9
Jackie Durkin (JD)	Administrator	Present for notes 1 – 9
Rupert Franklin (RF)	Commissioning Manager	Present for notes 1 – 3
Anthony Gildea (AG)	Technical Analyst	Present for notes 1 – 9
Kathryn Hopkins (KH)	Technical Adviser	Present for notes 1 – 9
Hannah Lomax (HL)	Technical Analyst - Health Economics	Present for notes 1 – 9
Yolanda Martinez (YM)	Technical Analyst	Present for notes 1 – 9
Vonda Murray (VM)	Project Manager	Present for notes 1 – 9
Benjamin Pearce (BP)	Editor	Present for notes 1 – 9
Susan Spiers (SS)	Associate Director	Present for notes 1 – 3

Philip Williams (PW)	Resource impact Lead	Present for notes 1 – 9
----------------------	----------------------	-------------------------

1. Welcome

VM, Project Manager provided some guidance on Zoom etiquette.

The Chair welcomed the committee members and attendees to the 1st committee meeting on Prostate Cancer. The Chair invited all attendees to introduce themselves.

The Chair outlined the objectives of the meeting, which included:

- Reviewing new evidence, and previous recommendations for:
 - In people with suspected prostate cancer (with any of the following symptoms - any lower urinary tract symptoms, such as nocturia, urinary frequency, hesitancy, urgency or retention or) erectile dysfunction or visible haematuria), what is the diagnostic accuracy of fixed PSA test threshold compared to age-adjusted PSA thresholds?
 - In people with localised or locally advanced prostate cancer, which risk stratification models/tools/categorising systems perform better in indicating risk of poor outcomes?

The Chair asked all committee members to verbally declare any new interests. The Chair and senior members of the Developer team noted that the interests declared did not prevent the attendees from fully participating in the meeting. The following interests were declared:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Ann Hoskins Chair	Independent Public Health (PH) Consultant	Advocate / member of the British Association of Child and Adolescent PH	Non-financial professional and personal interests	Declare and participate Not specific to the scope of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Private practice, mirrors NHS practice This includes plain film, CT, US and MRI reporting sessions and urology MDT and clinico-radiology meetings. Patients	Direct financial	Declare and participate. Rationale: Private practice in this area is a small proportion of

		tend to be relatively stable, with out-patient led, routine investigations in private practice. On the radiology on-call consultant rota for body imaging		the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Prostate Cancer UK, research advisory committee member	Non-financial professional and personal interests	Declare and participate. Rationale: Not scheduled to sit on any grant call committees at present, no control in regard to the grants to be reviewed.
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Member National Cancer Research Institute Prostate Clinical Studies Group	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary	British Society of	Non-	Declare and

	NHS Consultant Radiologist, Addenbrooke's Hospital	Urogenital Radiology, management committee member	financial professional and personal interests	participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Independent International Expert Clinical Reviewer for National Cancer Control Programme, Evidence-Based Cancer Guideline in Ireland	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	European Society of Urogenital Radiology, prostate working Group member (radiology MRI focused)	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	European Society of Urogenital Radiology, Prostate-Pathways subgroup, Vice-chair	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Close family member employed as Research Scientist, Drug Discovery at Astra Zeneca	Indirect financial	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Clinical Radiology editorial board member	Non-financial professional and personal interests	Declare and participate. Rationale: No control over the papers allocated, mostly

				imaging-based
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Principle Investigator, Research dynamic predictive model for baseline early detection and follow-up re-evaluation of the risk of prostate cancer progression on active surveillance (PROGRESS Prostate) Funded CRUK International Alliance for Cancer Early Detection (ACED)	Indirect financial	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Co-author, The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T1 relaxometry in patients with prostate cancer. Scientific Reports journal	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Co-author, MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. BJU International	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Co-author, ESUR/ESUI Consensus Statements on Multiparametric MRI for the Detection of Clinically Significant Prostate Cancer: Quality Requirements for Image Acquisition,	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline

		Interpretation and Radiologists' Training. European Radiology		
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Co-author, NPV of multi-parametric MRI in detection of clinically significant prostate cancer in the PI-RADS era: a systematic review and meta-analysis. European Urology	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	NICE committee member Transperineal biopsy in people with suspected prostate cancer	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Quality checkpoints in magnetic resonance imaging - Royal Society of Medicine: Radiology Section's Imaging and prostate cancer: Diagnosis, treatment and monitoring webinar	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke's Hospital	Speaker at the UK Imaging & Oncology Congress, 2021 High risk patient with potential curative intent - should we be doing more?	Non-financial professional and personal interests	Declare and participate. Rationale: Presentation covered current guidance using case examples
Tristan Barrett	Honorary NHS Consultant Radiologist, Addenbrooke	International Cancer Imaging Society (ICIS) - Masterclass in Imaging of Prostate Cancer (basic MRI	Non-financial professional and personal	Declare and participate. Rationale: Not specific

	's Hospital	interpretation)	interests	to the update of the guideline
Guy Chetiyawardana	Prostate Consultant Radiographer, Nottingham University Hospitals	Speaker at prostate cancer support groups on radiotherapy process and side effects, and advocating for patient voices in improving care	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Guy Chetiyawardana	Prostate Consultant Radiographer, Nottingham University Hospitals	Co-chair for Society of Radiographers prostate special interest group	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Guy Chetiyawardana	Prostate Consultant Radiographer, Nottingham University Hospitals	NIHR pre-doctoral award fellow-professional support and funding to support entry into doctoral level study	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Steve Hazell	Consultant in Histopathology, Royal Marsden NHS Trust	Royal Marsden, private practice, mirrors NHS work	Direct financial	Declare and participate. Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view

				that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully
Steve Hazell	Consultant in Histopathology, Royal Marsden NHS Trust	Involved in the PROFILE Prostate cancer Trials at Royal Marsden / ICR. The study is looking at how patients with a strong family history of prostate cancer are diagnosed / managed.	Non-financial professional and personal interests	Declare and participate. Rationale: Involvement with the trials is limited to assessing the prostate biopsies histopathology.
Steve Hazell	Consultant in Histopathology, Royal Marsden NHS Trust	Involved in and BARCODE1 Prostate cancer Trials at Royal Marsden / ICR. The study is looking at genetic screening of asymptomatic patients aged 50 to 69 to place individuals into risk levels of prostate cancer.	Non-financial professional and personal interests	Declare and participate. Rationale: Involvement with the trials is limited to assessing the prostate biopsies histopathology.
Steve Hazell	Consultant in Histopathology, Royal Marsden NHS Trust	Involved in the analysis of TRACERx Renal Consortium data at Royal Marsden. The study is related to renal cell carcinoma.	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Steve Hazell	Consultant in	Co-author- Detection	Non-	Declare and

	Histopathology, Royal Marsden NHS Trust	and staging of radio-recurrent prostate cancer using multiparametric Journal of Radiology	financial professional and personal interests	participate. Rationale: Not specific to the update of the guideline
Steve Hazell	Consultant in Histopathology, Royal Marsden NHS Trust	Co-author Pan-cancer analysis of whole genomes. Nature	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Steve Hazell	Consultant in Histopathology, Royal Marsden NHS Trust	Co-author Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of TMPRSS2-ERG Translocation With SOX2 Amplification. JCO Journal Oncology Practice	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	NICE Covid-19 rapid guideline on elective surgery guideline committee lay member	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Lay Representative Health Education England North-East	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba	Lay member	Lay Committee	Direct	Declare and

Joseph		Member on the General Pharmaceutical Council,	financial	participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Lay Partner Health and Care Professions Council	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	Royal College of Obstetrics and Gynaecology, Lay Examiner	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	NICE Perioperative care in adults guideline committee lay member	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Sheba Joseph	Lay member	NHS England & NHS Improvement, Patient and Public Voice Partner, Pastoral, Spiritual and Religious Support (Chaplaincy) Guidelines Steering Group	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Fundraising for Prostate Cancer UK	Indirect financial	Declare and participate. Rationale: Not specific to the update of the guideline

John Marshall	Lay Member	Awareness talks for Prostate Cancer UK, (travel and subsistence only).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Patient involvement to Prostate Cancer Research Group at Surrey University, (travel and subsistence only).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Patient involvement to Prostate Cancer Research Group at UCL, University, (travel and subsistence only).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Patient involvement to Prostate Cancer Research Group at Newcastle University, (travel and subsistence only).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Prostate Cancer Research advisory panel Cancer Research Advisory committee, (honorary paid on occasion, travel and subsistence only).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Prostate Cancer Research North West Cancers Research Advisory committee, (honorary paid on occasion, travel and	Direct financial	Declare and participate. Rationale: Not specific to the update of the

		subsistence only).		guideline
John Marshall	Lay Member	Lay member of Lancaster University Medical Schools, Learning and Teaching Committee (honarium and expenses).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Lay member of Lancaster University Medical Schools, student selection committee (honarium and expenses).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Lancaster University Medical Schools, lay interviewer of prospective medical students (honarium and expenses).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	Lay member of Lancaster University Medical Schools, Sponsorship Committee (honarium and expenses).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
John Marshall	Lay Member	NHS Cancer Programme volunteer, (travel and subsistence only).	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Associate Editor of the British Journal of General Practice – reviewing manuscripts	Direct financial	Declare and participate Rationale: Articles

		submitted for peer review publication in the BJGP, including those relating to cancer		published covering a breadth of topics including prostate cancer
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Study advisory group member for 'Diagnostic Journeys in Prostate Cancer' study. (Funded by Cancer Research Wales)	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Data Monitoring Committee member of FINESSE (Finasteride Evaluation in Surveillance for Prostate cancer) Trial (Funded by Yorkshire Cancer Research)	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Senior Editorial Board Member of BMC Cancer – reviewing manuscripts submitted for peer review publication in BM Cancer	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Doctoral fellowship funded by a Cancer Research UK Catalyst Award (The CanTest Collaborative)	Indirect financial	Declare and participate. Rationale: Not specific to the update of the guideline
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Lead author; Retrospective cohort study evaluating clinical, biochemical and pharmacological prognostic factors associated with	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the

		prostate cancer progression using routine primary care data. British Medical Journal		guideline
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Lead author; A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for Active Surveillance. BMC Urology	Non-financial professional and personal interests	Declare and participate. Rationale: Monitor if paper is included in the evidence review, and reassess.
Samuel Merriel	General Practitioner, Tyntesfield Medical Group	Early Detection and Diagnosis Project Award, from Cancer Research UK. Evaluating ethnic differences in blood markers of cancer in primary care	Indirect financial	Declare and participate. Rationale: Monitor if paper is included in the evidence review, and reassess.
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Private Medical Practice at Spire Cardiff Hospital in Urology	Direct financial	Declare and participate. Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for

				gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Chair, British Association of Urological Surgeons Oncology	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Secretary, British Association of Urological Surgeons Oncology	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Investigator add Aspirin,- Asprin vs placebo in cancer recurrence	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Principal investigator/co-Principal investigator UK Genetic Prostate Cancer Study- Hereditary prostate cancer study	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of	Investigator ARAMIS, - commercial trial in advanced prostate cancer	Non-financial professional and personal	Declare and participate. Rationale: Not specific

	Wales		interests	to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Principal investigator/co-Principal investigator ARAMIS Roll over-commercial trial in advanced prostate cancer	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Principal investigator/co-Principal investigator TRANSLATE- trial in set up phase	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Investigator Urinary Biomarkers, trial in early prostate cancer	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Principal investigator/co-Principal investigator TERRAIN-commercial trial in advanced prostate cancer	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	Principal investigator/co-Principal investigator TERRAIN extension-Commercial Trial in advanced prostate cancer	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Krishna Narahari	Consultant Urological Surgeon,	The organisation's research and development	Indirect financial	Declare and participate.

	University Hospital of Wales	unit has received clinical trial funding from the following organisations Medical Research Council, National Institute for Health Research. Charities such as; The Urology Foundation ,Prostate Cancer UK, Movember foundation		Rationale: Not specific to the update of the guideline Committee member has no influence over R&D funding and is not directly supported through R&D funding.
Krishna Narahari	Consultant Urological Surgeon, University Hospital of Wales	National Prostate Cancer Audit, Clinical Reference group and Project Group	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Brian Shine	Consultant Chemical Pathologist, Oxford University Hospitals	Research group investigating the variability of PSA, and relevance to the risk of developing metastatic prostate cancer. Currently seeking research funding through the NIH in the US.	Non-financial professional and personal interests	Declare and participate. Rationale: Monitor if the work is included in the evidence review, and reassess.
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	Private practice mirrors NHS work, self employed, based at the following locations; BMI Park Hospital Nottingham, Genesis care Nottingham, and Spire Hospital Nottingham.	Direct financial	Declare and participate. Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the

				need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	Conference ASCO 2021 meeting. (International meeting for all cancers). Registration fee Sponsorship from BAYER	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	Advisory boards BAYER, Bayer virtual round table meeting; TOPIC-Castration refractory non-metastatic prostate cancer.	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	Payments for speaking engagement/ advisory boards from BAYER. One meeting UK wide webinar; TOPIC-Castration refractory non-metastatic prostate cancer.	Direct financial	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham	Member of NHS England Specialised Urology CRG	Non-financial professional and	Declare and participate. Rationale:

	City Hospital		personal interests	Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	Member of Cancer-Research-UK sponsored National SACT Steering	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	UK chief investigator EORTC PEACE III trial in prostate Cancer.	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	UK chief investigator EORTC PEGASUS trial in prostate Cancer.	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	Co-author, Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. European Urology	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update of the guideline
Santhanam Sundar	Consultant in Clinical Oncology, Nottingham City Hospital	Co-author, Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration Resistant Prostate	Non-financial professional and personal interests	Declare and participate. Rationale: Not specific to the update

		Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). Journal of Clinical Oncology		of the guideline
Joanne Wortley	Consultant in Clinical Oncology, Nottingham City Hospital	Trustee – Registered Charity ProstaID	Indirect financial	Declare and participate. Rationale: Not specific to the update of the guideline

2. Introduction to NICE guideline development

The Chair introduced KH, Technical Adviser, who presented to the committee an introduction to how NICE develop a guideline. The Chair thanked KH for her presentation.

3. RQ - In people with suspected prostate cancer (with any of the following symptoms - any lower urinary tract symptoms, such as nocturia, urinary frequency, hesitancy, urgency or retention or) erectile dysfunction or visible haematuria), what is the diagnostic accuracy of fixed PSA test threshold compared to age-adjusted PSA thresholds?

- Review approach
- Evidence presentation
- Evidence discussion

The Chair introduced AG, Technical Analyst, who provided an outline of the evidence review approach, and presented the evidence for people with suspected prostate cancer with a pre-defined set of symptoms, what is the diagnostic accuracy of fixed PSA test threshold compared to age-adjusted PSA thresholds. The Chair thanked AG for his presentation.

The Chair facilitated discussion.

4. RQ - In people with suspected prostate cancer (with any of the following symptoms - any lower urinary tract symptoms, such as nocturia, urinary frequency, hesitancy, urgency or retention or) erectile dysfunction or visible haematuria), what is the diagnostic accuracy of fixed PSA test threshold compared to age-adjusted PSA thresholds?

- Health Economics discussion

The Chair introduced LB Technical Adviser Health Economics, and SA Technical Analyst Health Economics provided a presentation on health economics for the

review question. The Chair thanked LB and SA for their presentation.

5. RQ - In people with suspected prostate cancer (with any of the following symptoms - any lower urinary tract symptoms, such as nocturia, urinary frequency, hesitancy, urgency or retention or) erectile dysfunction or visible haematuria), what is the diagnostic accuracy of fixed PSA test threshold compared to age-adjusted PSA thresholds?

- **Drafting recommendations**

The Chair facilitated recommendation discussion.

6. RQ - In people with localised or locally advanced prostate cancer, which risk stratification models/tools/categorising systems perform better in indicating risk of poor outcomes?

- **Review approach**
- **Evidence presentation**
- **Evidence discussion**

The Chair introduced YM, Technical Analyst, who provided an outline of the evidence review approach, and presented the evidence for people with localised or locally advanced prostate cancer, which risk stratification models/tools/categorising systems perform better in indicating risk of poor outcomes. The Chair thanked YM for her presentation.

The Chair facilitated discussion.

7. RQ - In people with localised or locally advanced prostate cancer, which risk stratification models/tools/categorising systems perform better in indicating risk of poor outcomes?

- **Health Economics discussion**

The Chair introduced LB Technical Adviser Health Economics, and HL Technical Analyst Health Economics provided a presentation on health economics for the review question. The Chair thanked LB and HL for their presentation.

The Chair facilitated discussion.

8. RQ - In people with localised or locally advanced prostate cancer, which risk stratification models/tools/categorising systems perform better in indicating risk of poor outcomes?

- **Drafting recommendations**

The Chair facilitated recommendation discussion.

9. AOB and Summary

VM, Project Manager summarised the next steps, and KH provided an overview of what will be covered at GComm2. The Chair thanked the committee for their time and contribution to the meeting. The Chair reminded the committee the date of the next committee meeting, timings to be confirmed.

Date of next meeting: Wednesday 15th September

Location of next meeting: Zoom